Lillian Kim

Lillian Kim

Partner
Lillian Kim
New York
+1 212 459 7110

Lillian Kim is a corporate partner and member of the firm’s Public M&A/Corporate Governance and Technology and Life Sciences groups. Lillian focuses her practice on advising public companies, boards of directors and special committees, and private equity firms in connection with mergers and acquisitions, strategic investments and other significant corporate matters. She also advises clients on corporate governance and securities law disclosure and compliance. She has represented clients across a broad range of industries, including healthcare, pharmaceuticals, biotechnology, information technology, software, financial services, retail and consumer products, and real estate.

Lillian serves as a member of the firm’s New York Hiring Committee, Women’s Initiative, and the Committee on Racial and Ethnic Diversity.

Experience

Lillian’s notable representations include:

Technology

  • Mimecast in its $5.8 billion sale to Permira
  • Slack Technologies in its $27.7 billion sale to Salesforce
  • Virtusa Corporation in its $2 billion sale to Baring Private Equity Asia
  • Help/Systems in its $217 million take-private of GlobalSCAPE
  • Monotype Imaging in its $825 million sale to HGGC
  • Imprivata in its $544 million sale to Thoma Bravo
  • Opower in its $532 million sale to Oracle
  • Planet Payment in its $257 million sale to Fintrax Group

Life Sciences

  • Forma Therapeutics in its $1.1 billion sale to Novo Nordisk
  • Trillium Therapeutics in its $2.3 billion sale to Pfizer
  • Chiasma in its sale to Amryt Pharma
  • Special Committee of NantKwest in NantKwest’s merger with ImmunityBio
  • PAREXEL International in its $5 billion sale to Pamplona Capital Management
  • Teva Pharmaceutical in its $3.2 billion acquisition of Auspex Pharmaceuticals
  • AMAG Pharmaceuticals in its $500 million sale to Covis Pharma, an Apollo Global Management company
  • Ocata Therapeutics in its $380 million sale to Astellas Pharma
  • Dimension Therapeutics in its $151 million sale to Ultragenyx Pharmaceutical
  • Juniper Pharmaceuticals in its $139 million sale to Catalent
  • Neon Therapeutics in its $97 million sale to BioNTech

Other

  • TIER REIT in its $7.8 billion merger with Cousins Properties
  • Amplify Snack Brands in its $1.6 billion sale to The Hershey Company

Professional Experience

Prior to joining Goodwin, Lillian practiced with Fried, Frank, Harris, Shriver & Jacobson LLP and Linklaters LLP.

Credentials

Education

JD

University of Pennsylvania Law School

CBPP

The Wharton School at the University of Pennsylvania

BA

Wellesley College

Admissions

Bars

  • New York
  • California

Recognition & Awards

In 2022, Lillian was selected to join the Leadership Council on Legal Diversity Fellows Program.

Lillian was recognized by Lawdragon as one of the 500 Leading Dealmakers in America, with particular emphasis on Technology/Life Sciences M&A and Corporate Governance (2021 and 2022).

While attending law school, Lillian was a senior editor for the University of Pennsylvania Journal of Business Law.

Publications

Lillian was a co-author of the article titled “The PropTech Industry is Set for a Wave of Consolidation,” produced by Goodwin’s PropTech Pulse thought leadership series in March 2019.